Aagama Exports LLP Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Aagama Exports LLP Pharmaceutical Export Portfolio Dataset — 2 Products, $478.1K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Aagama Exports LLP — Pharmaceutical Exporter Profile (2026) | 2 Products, $478.1K Trade | TransData Nexus

Aagama Exports LLP

Indian Pharmaceutical Exporter · Antivirals Specialist · $478.1K Total Trade · DGFT Verified

Aagama Exports LLP is an Indian pharmaceutical exporter with a total trade value of $478.1K across 2 products in 2 therapeutic categories. Based on 12 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Efavirenz ($285.1K), Ritonavir ($193.0K), .

Aagama Exports LLP — Export Portfolio & Destination Treemap

Aagama Exports LLP pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Aagama Exports LLP? — Company Overview & Market Position

Aagama Exports LLP is a pharmaceutical exporter based in Hyderabad, Telangana, India. Established on August 22, 2019, the company operates under the Corporate Identification Number (CIN) AAQ-3386. The registered office is located at Plot 335, HMT Swarna Puri Colony, Ameenpur, Hyderabad, Telangana, 502032. The firm's total obligation of contribution is ₹0.10 million, indicating a modest capital base. As of the latest available data, the company has two active designated partners: Yerrapragada Kusuma Madhavi and Venkata Sai Ramya Ravinuthala. Financial details such as annual revenue and employee count are not publicly disclosed. The company's official website is aagamaexports.com.

What Does Aagama Exports LLP Export? — Product Portfolio Analysis

Top Products by Export Value

1Efavirenz$285.1K 2Ritonavir$193.0K

Aagama Exports LLP Therapeutic Categories — 2 Specializations

Product Portfolio — Top 2 by Export Value

Aagama Exports LLP exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Efavirenz	Antivirals	$285.1K	7	0.5%	11
2	Ritonavir	Antiviral & HIV Medications	$193.0K	5	0.1%	11

Aagama Exports LLP exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $478.1K. The top category is Antivirals (59.6% of portfolio), followed by Antiviral & HIV Medications (40.4%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Aagama Exports LLP — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Aagama Exports LLP does not own or operate any manufacturing facilities. The company focuses on the export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. These products are sourced from third-party manufacturers, as evidenced by their product offerings in activated carbon, chemicals, and IR 64 parboiled rice. The absence of in-house manufacturing suggests a reliance on contract manufacturing arrangements to fulfill export orders.

3Key Leadership

The leadership team of Aagama Exports LLP comprises two designated partners:

Yerrapragada Kusuma Madhavi: Appointed on August 22, 2019, she has been associated with the company since its inception.

Venkata Sai Ramya Ravinuthala: Joined as a designated partner on July 17, 2025, indicating a recent addition to the leadership team.

There is no publicly available information regarding other key executives or their specific roles within the company.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Aagama Exports LLP Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Aagama Exports LLP's export activities are primarily focused on markets in South Asia, notably Bangladesh and Sri Lanka. The company's trade data indicates significant export volumes to these countries, with Bangladesh being a major destination. However, there is no publicly available information regarding the company's presence or regulatory approvals in other regulated markets such as the United States, European Union, United Kingdom, Australia, or Japan. This suggests that Aagama Exports LLP's operations are currently concentrated in the South Asian region.

2Emerging Markets

Aagama Exports LLP has demonstrated a strong presence in emerging markets, particularly in South Asia. The company's export data highlights substantial trade with Bangladesh and Sri Lanka, indicating a strategic focus on these regions. While there is no specific information regarding the company's activities in Africa, Latin America, or Southeast Asia, the existing trade patterns suggest potential for expansion into these emerging markets. The company's adherence to international quality standards, as evidenced by its product offerings, may facilitate entry into these regions.

3Geographic Strategy

Aagama Exports LLP — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

There is no publicly available information regarding Aagama Exports LLP's registration with the U.S. Food and Drug Administration (FDA), approval of Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or inspection history. This absence suggests that the company may not currently export pharmaceutical products to the United States or may not have pursued FDA approvals for its products.

2WHO & EU GMP

Aagama Exports LLP's product offerings include activated carbon and chemicals, which are not pharmaceutical products. Therefore, there is no publicly available information regarding the company's compliance with World Health Organization (WHO) prequalification, European Union Good Manufacturing Practice (EU GMP) certificates, or European Directorate for the Quality of Medicines & HealthCare (EDQM) status. The company's focus on non-pharmaceutical products may limit its engagement with these specific certifications.

3CDSCO & Indian Regulatory

Aagama Exports LLP — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Aagama Exports LLP operates in the pharmaceutical export sector, focusing on finished pharmaceutical formulations. While specific competitors are not identified in the available data, the company's trade patterns indicate competition with other exporters in the South Asian region. The absence of in-house manufacturing may position the company differently compared to competitors with integrated manufacturing capabilities.

2Key Differentiators

Aagama Exports LLP's key differentiators include its focus on non-pharmaceutical products such as activated carbon and chemicals, which may appeal to a different customer base compared to traditional pharmaceutical exporters. Additionally, the company's concentration on South Asian markets allows for specialized market knowledge and relationships.

3Strategic Position

Aagama Exports LLP's current strategic direction appears to be centered on exporting non-pharmaceutical products to South Asian markets. The company's future outlook may involve expanding its product portfolio to include pharmaceutical formulations and exploring new markets to diversify its revenue streams.

Buyer Due Diligence Brief — Evaluating Aagama Exports LLP as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Aagama Exports LLP's track record in exporting non-pharmaceutical products is demonstrated by its trade data, indicating consistent export volumes to Bangladesh and Sri Lanka. The company's reliance on third-party manufacturers for pharmaceutical products suggests a need for careful evaluation of supplier reliability and product quality.

2Certifications to Verify

Importers should verify the following certifications when considering products from Aagama Exports LLP:

FDA Registration: To ensure compliance with U.S. regulations for pharmaceutical products.

WHO-GMP: To confirm adherence to international manufacturing standards.

EU GMP: To verify compliance with European manufacturing practices.

Frequently Asked Questions — Aagama Exports LLP

How many pharmaceutical products does Aagama Exports LLP export from India?

Aagama Exports LLP exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Efavirenz ($285.1K), Ritonavir ($193.0K). Total export value is $478.1K.

What is Aagama Exports LLP's total pharmaceutical export value?

Aagama Exports LLP's total pharmaceutical export value is $478.1K, based on 12 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Aagama Exports LLP cover?

Aagama Exports LLP exports across 2 therapeutic categories. The largest are Antivirals (59.6%, 1 products), Antiviral & HIV Medications (40.4%, 1 products).

Get Full Aagama Exports LLP Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.